Survival analysis in familial ovarian cancer, a case control study

被引:22
作者
Zweemer, RP
Verheijen, RHM [1 ]
Coebergh, JWW
Jacobs, IJ
van Diest, PJ
Gille, JJP
Skates, S
Menko, FH
Ten Kate, LP
Kenemans, P
机构
[1] Vrije Univ Amsterdam, Med Ctr, Dept Obstet & Gynaecol, Amsterdam, Netherlands
[2] Comprehens Canc Ctr S, Eindhoven, Netherlands
[3] Erasmus Univ, Rotterdam, Netherlands
[4] St Bartholomews Hosp, Gynaecol Canc Res Unit, London, England
[5] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, Amsterdam, Netherlands
[6] Vrije Univ Amsterdam, Med Ctr, Dept Clin & Human Genet, Amsterdam, Netherlands
[7] Harvard Univ, Sch Med, Dept Med, Boston, MA USA
[8] Harvard Univ, Sch Med, Dept Biostat, Boston, MA USA
[9] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
[10] Massachusetts Gen Hosp, Dept Biostat, Boston, MA 02114 USA
关键词
ovarian cancer; hereditary; survival; BRCA1; BRCA2;
D O I
10.1016/S0301-2115(01)00318-9
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: familial ovarian cancer patients have been found to differ from sporadic cases, clinically as well as in the molecular make-up of the tumour. Here, a case control study is performed to analyse potential differences in survival. Study design: 31 families with a strong history of ovarian and/or breast cancer presenting to a family cancer clinic 44 ovarian cancer patients were included. Each patient was matched for age and stage with controls from a cancer registry. Survival rates and the effect of several prognostic factors were analysed. Results: median survival in the study group differed significantly from controls. A survival benefit for familial cases was maintained up to 5 years after diagnosis. Long-term survival was equally poor in both groups. Conclusion: the difference in survival between familial ovarian cancer cases and matched controls may reflect differences in biological behaviour. This may have important implications for the management and prevention of familial ovarian cancer. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:219 / 223
页数:5
相关论文
共 29 条
[1]   IMPROVED PROGNOSIS OF OVARIAN-CANCER IN THE NETHERLANDS DURING THE PERIOD 1975-1985 - A REGISTRY-BASED STUDY [J].
BALVERTLOCHT, HR ;
COEBERGH, JWW ;
HOP, WCJ ;
BROLMANN, HAM ;
CROMMELIN, M ;
VANWIJCK, DJAM ;
VERHAGENTEULINGS, MTCIJ .
GYNECOLOGIC ONCOLOGY, 1991, 42 (01) :3-8
[2]  
BERCHUCK A, 1990, CANCER RES, V50, P4087
[3]   Clinicopathologic features of BRCA-linked and sporadic ovarian cancer [J].
Boyd, J ;
Sonoda, Y ;
Federici, MG ;
Bogomolniy, F ;
Rhei, E ;
Maresco, DL ;
Saigo, PE ;
Almadrones, LA ;
Barakat, RR ;
Brown, CL ;
Chi, DS ;
Curtin, JP ;
Poynor, EA ;
Hoskins, WJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (17) :2260-2265
[4]   An evaluation of prognostic factors in advanced ovarian cancer [J].
Brinkhuis, M ;
Meijer, GA ;
Baak, JPA .
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1995, 63 (02) :115-124
[5]  
Brunet JS, 1997, NEW ENGL J MED, V336, P1256
[6]  
COEBERGH JJW, 1995, CANC OVARY CANC INCI, P62
[7]  
Foster KA, 1996, CANCER RES, V56, P3622
[8]   Quantification of p53 in epithelial ovarian cancer [J].
Geisler, JP ;
Geisler, HE ;
Wiemann, MC ;
Givens, SS ;
Zhou, Z ;
Miller, GA .
GYNECOLOGIC ONCOLOGY, 1997, 66 (03) :435-438
[9]   Clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease [J].
Goff, BA ;
delaCuesta, RS ;
Muntz, HG ;
Fleischhacker, D ;
Ek, M ;
Rice, LW ;
Nikrui, N ;
Tamimi, HK ;
Cain, JM ;
Greer, BE ;
Fuller, AF .
GYNECOLOGIC ONCOLOGY, 1996, 60 (03) :412-417
[10]   RAPID DETECTION OF BRCA1 MUTATIONS BY THE PROTEIN TRUNCATION TEST [J].
HOGERVORST, FBL ;
CORNELIS, RS ;
BOUT, M ;
VANVLIET, M ;
OOSTERWIJK, JC ;
OLMER, R ;
BAKKER, B ;
KLIJN, JGM ;
VASEN, HFA ;
MEIJERSHEIJBOER, H ;
MENKO, FH ;
CORNELISSE, CJ ;
DENDUNNEN, JT ;
DEVILEE, P ;
VANOMMEN, GJB .
NATURE GENETICS, 1995, 10 (02) :208-212